Document Detail

Low glycemic index treatment for epilepsy in tuberous sclerosis complex.
MedLine Citation:
PMID:  22119636     Owner:  NLM     Status:  Publisher    
Retrospective chart review of 15 patients with tuberous sclerosis complex (TSC) who initiated the low glycemic index treatment (LGIT) for epilepsy management at Massachusetts General Hospital over a five-year period. Prior to dietary therapy, this cohort (average age: 8.5 years) had tried an average of 5.8 anti-epileptic drugs with incomplete seizure control. At 6 months on the LGIT, 7/15 (47%) patients experienced >50% reduction in seizure frequency.
Anna M Larson; Heidi H Pfeifer; Elizabeth A Thiele
Related Documents :
11851676 - Botulinum toxin a in the treatment of patients with frey syndrome.
10796916 - Treatment of iatrogenic femoral arterial pseudoaneurysms: comparison of us-guided throm...
16012436 - Treatment of recalcitrant intermetatarsal neuroma with 4% sclerosing alcohol injection:...
19965856 - Kinematic improvement following botulinum toxin-a injection in upper-limb spasticity du...
18523796 - A pilot study of intravitreal bevacizumab for the treatment of central serous chorioret...
2696506 - Onset of action between bupivacaine 0.5% and bupivacaine 0.5% plus fentanyl 75 mcg.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-11-23
Journal Detail:
Title:  Epilepsy research     Volume:  -     ISSN:  1872-6844     ISO Abbreviation:  -     Publication Date:  2011 Nov 
Date Detail:
Created Date:  2011-11-28     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8703089     Medline TA:  Epilepsy Res     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2011. Published by Elsevier B.V.
Department of Neurology, Massachusetts General Hospital, Boston, MA, United States.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Superoxide dismutase 2 Val16Ala polymorphism is a risk factor for the valproic acid-related elevatio...
Next Document:  Conversion from enzyme-inducing antiepileptic drugs to topiramate: effects on lipids and C-reactive ...